Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 3,709 shares of the company’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total transaction of $167,758.07. Following the completion of the transaction, the vice president now owns 17,500 shares of the company’s stock, valued at $791,525. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) traded up 3.05% during midday trading on Wednesday, hitting $45.65. 1,128,367 shares of the stock traded hands. The stock’s 50-day moving average price is $42.54 and its 200 day moving average price is $34.58. The company has a market capitalization of $2.31 billion, a price-to-earnings ratio of 23.03 and a beta of 1.31. Supernus Pharmaceuticals, Inc. has a 52 week low of $17.25 and a 52 week high of $46.45.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, beating the Zacks’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The company had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. On average, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/16/padmanabh-p-bhatt-sells-3709-shares-of-supernus-pharmaceuticals-inc-supn-stock.html.

Large investors have recently bought and sold shares of the stock. Pinebridge Investments L.P. raised its stake in Supernus Pharmaceuticals by 1.3% in the second quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock worth $285,000 after buying an additional 86 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Supernus Pharmaceuticals by 0.5% in the second quarter. Louisiana State Employees Retirement System now owns 20,500 shares of the specialty pharmaceutical company’s stock worth $884,000 after buying an additional 100 shares in the last quarter. Arizona State Retirement System raised its stake in Supernus Pharmaceuticals by 0.4% in the second quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock worth $1,129,000 after buying an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Supernus Pharmaceuticals by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock worth $1,579,000 after buying an additional 128 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its stake in Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 170 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a research report on Thursday, July 13th. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $34.00 to $49.00 and gave the stock a “buy” rating in a research report on Wednesday, July 5th. Jefferies Group LLC increased their price objective on shares of Supernus Pharmaceuticals from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, June 28th. Stifel Nicolaus reiterated a “buy” rating and set a $47.00 price objective (up from $36.00) on shares of Supernus Pharmaceuticals in a research report on Tuesday, July 18th. Finally, BidaskClub cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $48.43.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Insider Buying and Selling by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.